SCHEMBL5056565

SCHEMBL5056565

CC(C)Nc1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4scnc4c3)c(F)c2)ccn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 9/20 0.59
MAPK13 O15264 2/20 0.57
BRAF P15056 10/20 0.56
ABL1 P00519 3/20 0.56
PLK4 O00444 1/20 0.56
ACOX3 O15254 1/20 0.56
MAP3K7 O43318 1/20 0.56
DYRK3 O43781 1/20 0.56
JAK2 O60674 1/20 0.56
ERN1 O75460 1/20 0.56
RPS6KA4 O75676 1/20 0.56
STK10 O94804 1/20 0.56
MAP4K4 O95819 1/20 0.56
RAF1 P04049 1/20 0.56
NTRK1 P04629 1/20 0.56
LCK P06239 1/20 0.56
FYN P06241 1/20 0.56
CDK1 P06493 1/20 0.56
FES P07332 1/20 0.56
CSF1R P07333 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5055008 0.92 MAPK14 (0.48) MAPK14MAPK13BRAFABL1PLK4
SCHEMBL5055320 0.92 MAPK14 (0.70) MAPK14MAPK13BRAFABL1PLK4
SCHEMBL5052232 0.90 ABL1 (0.57) MAPK14MAPK13BRAFABL1RAF1
SCHEMBL5060186 0.90 MAPK14 (0.58) MAPK14MAPK13BRAFABL1PLK4
SCHEMBL5060308 0.87 BRAF (0.74) MAPK14MAPK13BRAFABL1PLK4
SCHEMBL5054900 0.86 MAPK14 (0.59) MAPK14MAPK13BRAFABL1PLK4
SCHEMBL5052234 0.86 MAPK14 (0.59) MAPK14MAPK13BRAFABL1PLK4
SCHEMBL2027848 0.85 MAPK14 (0.76) MAPK14MAPK13BRAFABL1PLK4
SCHEMBL5062669 0.85 MAPK14 (0.57) MAPK14MAPK13BRAFABL1PLK4
SCHEMBL5060171 0.84 MAPK14 (0.65) MAPK14MAPK13BRAFABL1PLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2008-05-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS ABL2, BRAF, MAP3K1 MAPK14 100/4885MAPK13 118/4885BRAF 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.